Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of adjunctive troriluzole in obsessive-compulsive disorder
NL-OMON52032Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of troriluzole in obsessive compulsive disorder (OCD), sponsored by Pfizer. Primary endpoints: Serious adverse events, Adverse events leading to discontinuation and 2 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NL-OMON52032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52032.